Similar depletion of protective Faecalibacterium prausnitzii in psoriasis and inflammatory bowel disease, but not in hidradenitis suppurativa

Journal of Crohn's and Colitis

Volumn 10, Issue 9, 2016, Pages 1067-1075

  Eppinga, Hester ^a   Sperna Weiland, Christa J ^a   Thio, H Bing ^a   van der Woude, C Janneke ^a   Nijsten, Tamar E C ^a   Peppelenbosch, Maikel P ^a   Konstantinov, Sergey R ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Crohn's disease; Escherichia coli; Faecalibacterium prausnitzii; Gastrointestinal microbiome; Hidradenitis suppurativa; Inflammatory bowel diseases; Microbiota; Psoriasis; Skin diseases; Skin manifestations; Ulcerative colitis

Indexed keywords

CALGRANULIN; DNA;

ADULT; ARTICLE; BACTERIAL COLONIZATION; CONTROLLED STUDY; DEPLETION; DNA EXTRACTION; ESCHERICHIA COLI; FAECALIBACTERIUM PRAUSNITZII; FECES ANALYSIS; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MICROBIAL COMMUNITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSORIASIS; SUPPURATIVE HIDRADENITIS; ADOLESCENT; AGED; CASE CONTROL STUDY; FECES; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; ESCHERICHIA COLI; FAECALIBACTERIUM PRAUSNITZII; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HIDRADENITIS SUPPURATIVA; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PSORIASIS; YOUNG ADULT;

EID: 85012237685     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw070     Document Type: Article

References (34)

1. De Hertogh G, Aerssens J, Geboes KP, Geboes K. Evidence for the involvement of infectious agents in the pathogenesis of Crohn's disease. World J Gastroenterol 2008;14:845-52.
2. O'Brien CL, Allison GE, Pavli P. The more the merrier: Faecalibacterium prausnitzii in Crohn's disease. J Gastroenterol Hepatol 2013;28:757-9.
3. Berry D, Reinisch W. Intestinal microbiota: A source of novel biomarkers in inflammatory bowel diseases? Best Pract Res Clin Gastroenterol 2013;27:47-58.
4. Scarpa R, Manguso F, D'Arienzo A, et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol 2000;27:1241-6.
5. Christophers E. Comorbidities in psoriasis. Clin Dermatol 2007;25:529-34.
6. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol 2003;48:805-21; quiz 22-4.
7. Janse IC, Koldijk MJ, Spekhorst LM, et al. Identification of clinical and genetic parameters associated with hidradenitis suppurativa in inflammatory bowel disease. Inflamm Bowel Dis 2015. PMID: 26422515.
8. van der Zee HH, van der Woude CJ, Florencia EF, Prens EP. Hidradenitis suppurativa and inflammatory bowel disease: Are they associated? Results of a pilot study. Br J Dermatol 2010;162:195-7.
9. Scher JU, Ubeda C, Artacho A, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheum 2015;67:128-39.
10. Fry L, Baker BS, Powles AV, Fahlen A, Engstrand L. Is chronic plaque psoriasis triggered by microbiota in the skin? Br J Dermatol 2013;169:47-52.
11. Olsen T, Rismo R, Cui G, et al. Th1 and th17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine 2011;56:633-40.
12. Krueger JG. Hiding under the skin: A welcome surprise in psoriasis. Nat Med 2012;18:1750-1.
13. Purchiaroni F, Tortora A, Gabrielli M, et al. The role of intestinal microbiota and the immune system. Eur Rev Med Pharmacol Sci 2013;17:323-33.
14. Fujimoto T, Imaeda H, Takahashi K, et al. Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease. J Gastroenterol Hepatol 2013;28:613-9.
15. Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011;60:631-7.
16. Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014;63:1275-83.
17. Lopez-Siles M, Khan TM, Duncan SH, et al. Cultured representatives of two major phylogroups of human colonic Faecalibacterium prausnitzii can utilize pectin, uronic acids, and host-derived substrates for growth. Appl Environ Microbiol 2012;78:420-8.
18. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008;105:16731-6.
19. Rajca S, Grondin V, Louis E, et al. Alterations in the intestinal microbiome [dysbiosis] as a predictor of relapse after infliximab withdrawal in Crohn's disease. Inflamm Bowel Dis 2014;20:978-86.
20. Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous clostridium species. Science 2011;331:337-41.
21. Qiu X, Zhang M, Yang X, Hong N, Yu C. Faecalibacterium prausnitzii upregulates regulatory t cells and anti-inflammatory cytokines in treating TNBS-induced colitis. J Crohns Colitis 2013;7:558-68.
22. Sipponen T. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin. Dig Dis 2013;31:336-44.
23. Lopez-Siles M, Martinez-Medina M, Busquets D, et al. Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish irritable bowel syndrome and inflammatory bowel disease phenotypes. Int J Med Microbiol 2014;304:464-75.
24. Furet JP, Firmesse O, Gourmelon M, et al. Comparative assessment of human and farm animal faecal microbiota using real-time quantitative PCR. FEMS Microbiol Ecol 2009;68:351-62.
25. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
26. Willing B, Halfvarson J, Dicksved J, et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm Bowel Dis 2009;15:653-60.
27. Martinez-Medina M, Aldeguer X, Gonzalez-Huix F, Acero D, Garcia-Gil LJ. Abnormal microbiota composition in the ileocolonic mucosa of Crohn's disease patients as revealed by polymerase chain reaction-denaturing gradient gel electrophoresis. Inflamm Bowel Dis 2006;12:1136-45.
28. Cao Y, Shen J, Ran ZH. Association between Faecalibacterium prausnitzii reduction and inflammatory bowel disease: A meta-analysis and systematic review of the literature. Gastroenterol Res Pract 2014;2014:872725.
29. Miquel S, Martin R, Rossi O, et al. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol 2013;16:255-61.
30. Quévrain E, Maubert MA, Michon C, et al. Identification of an antiinflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. Gut 2016;65:415-25.
31. Khan MT, van Dijl JM, Harmsen HJM. Antioxidants keep the potentially probiotic but highly oxygen-sensitive human gut bacterium Faecalibacterium prausnitzii alive at ambient air. PLoS One 2014;9:e96097.
32. Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies. J Am Acad Dermatol 2008;59:596-601.
33. Benjamin JL, Hedin CRH, Koutsoumpas A, et al. Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. Inflamm Bowel Dis 2012;18:1092-100.
34. Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor gpr43. Nature 2009;461:1282-6.